Statera Biopharma, Inc.
CBLI evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Lead Asset:
- entolimod (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CBLI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
entolimod (Phase 1)
Next Catalyst
—
Tracking 4 pipeline candidates for Statera Biopharma, Inc..
Similar companies
Run Statera Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Statera Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Statera Biopharma, Inc.'s lead drug candidate?
Statera Biopharma, Inc.'s most advanced tracked candidate is entolimod (Phase 1) for Acute Radiation Syndrome (ARS) and Oncology.
Who is the CEO of Statera Biopharma, Inc.?
Michael K. Handley is the chief executive officer of Statera Biopharma, Inc. (CBLI).
What therapeutic areas does Statera Biopharma, Inc. focus on?
Statera Biopharma, Inc. develops therapies across Oncology, Neurology, Immunology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.